Israel's IceCure says gets FDA nod to treat tumours in liver, kidney
Israel's IceCure Medical said on Sunday it received U.S. regulatory approval to expand the use of its cryoablation technology to treat benign and cancerous tumours in livers and kidneys, sending its share price up 30%. IceCure's treatment uses special needles to inject liquid nitrogen to freeze and destroy tumours without the need for surgery. It has focused on breast tumours, but now the U.S. Food and Drug Administration (FDA) approved new uses, such as against tumours in the kidney, liver and in the fields of neurology and ear, nose and throat, the company said. The FDA also approved its new MultySense system that has three probes, it said. Its earlier system had one needle.
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
